Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Cencora (COR) Expected to Post Quarterly Earnings on Wednesday

Cencora logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

Cencora (NYSE:COR - Get Free Report) is expected to be announcing its Q4 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $4.58 per share and revenue of $87.95 billion for the quarter. Investors can find conference call details on the company's upcoming Q4 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analysts' expectations of $84.31 billion. The company's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $4.00 earnings per share. On average, analysts expect Cencora to post $17.87 EPS for the current fiscal year and $19.77 EPS for the next fiscal year.

Cencora Stock Down 1.5%

Shares of COR stock opened at $325.09 on Wednesday. The stock has a market cap of $62.04 billion, a price-to-earnings ratio of 24.15 and a beta of 0.58. Cencora has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm's 50 day moving average price is $322.60 and its two-hundred day moving average price is $317.67.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora's dividend payout ratio (DPR) is presently 17.83%.

Insider Transactions at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the company's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company's stock, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.38% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research analyst reports. Evercore restated an "outperform" rating and issued a $350.00 price target (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Argus increased their price objective on shares of Cencora from $340.00 to $380.00 and gave the company a "buy" rating in a research note on Tuesday, October 20th. UBS Group decreased their price objective on shares of Cencora from $430.00 to $400.00 and set a "buy" rating for the company in a report on Friday, October 16th. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Citigroup reissued a "buy" rating on shares of Cencora in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $366.44.

Check Out Our Latest Analysis on Cencora

Cencora Company Profile

(Get Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.

Featured Articles

Earnings History for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines